

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF
03 MAR -3**LOBBYING REPORT**


Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Dermagraft Joint Venture			
2. Address <input type="checkbox"/> Check if different than previously reported 1615 L Street, NW Suite 650 Washington, DC 20036			
3. Principal Place of Business (if different from line 2) City: La Jolla, CA 92037 State/Zip (or Country)			
4. Contact Name Mary E. Hayter		Telephone 202.626.8235	E-mail (optional) mary.hayter@smith-nephew.com
7. Client Name <input type="checkbox"/> Self			5. Senate ID # 6. House ID # 35541

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-December 31)
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇒ Termination Date December 31, 2002 11. No Lobbying **INCOME OR EXPENSES** - Complete Either Line 12 OR Line 13

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input checked="" type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 603 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code</p>
---	---

Signature



Signature _____

Printed Name and Title Mary E. Hayter Manager, Health
Economics

LD-2 (REV. 6/98)

P

Registrant Name Dermagraft Joint Venture Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

Food and Drug Administration Appropriations - FY 2003
Food and Drug Administration Reauthorization - User Fees

17. House(s) of Congress and Federal agencies contacted Check if None

**United States House
of Representatives**

United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary E. Hayter	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Mary E. Hayter Date February 12, 2003

Signature _____

Printed Name and Title Mary E. Hayter

Manager, Health Economics

Form LD-2 (Rev.6/98)

Page

DermaGraft Joint
Registrant Name Venture Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

*Medicare Regulatory Reform - Competition Acquisition
Hospital Outpatient PPS (Pass-through Payment)
Hospital Inpatient New Technology DRG*

17. House(s) of Congress and Federal agencies contacted

Check if None

**United States House
of Representatives**

**Centers for Medicare
and Medicaid**

United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary E. Hayter	
.....
.....
.....
.....
.....
.....
.....
.....

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Mary E. Hayter

Date February 12, 2

Signature _____

Printed Name and Title Mary E. Hayter Manager, Health Economics

Form LD-2 (Rev.6/98)

Page

Registrant Name Dermagraft Joint Venture Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Prescription Drug Issues - medicare / medicaid

17. House(s) of Congress and Federal agencies contacted

Check if None

**United States House
of Representatives**

United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary E. Hayter	
.....
.....
.....
.....
.....
.....
.....
.....

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Maria S. [Signature]

Date *February 12, 2011*

Signature Mary E. Hayter Date 1/11/2011

Printed Name and Title Mary E. Hayter Manager, Health Economics

Registrant Name Dermagraft Joint Venture Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

*Prescription Drugs - Medicare/Medicaid
FDA Device Reauthorization, User Fees*

17. House(s) of Congress and Federal agencies contacted

Check if None

**United States House
of Representatives**

United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary E. Hayter	
.....
.....
.....
.....
.....
.....
.....
.....

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature Mary E. Hayter Date February 12, 20

Printed Name and Title Mary E. Hayter Manager, Health
Economics

Form LD-2 (Rev.6/98)

Page .